SCOTTSDALE, AZ, June 11, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – CBD Life Sciences Inc. (OTC: CBDL) is pleased to announce that its wholly owned subsidiary, LBC Bioscience, has completed the development of a disposable CBD vape-pen. The product is now undergoing final market testing and is expected to be available for purchase within the next three to four weeks.
The CBD oil market is currently estimated to be $1.5 billion and some industry experts project it to grow to over $16 billion by 2025. Combine that with the e-cigarette vaping sector which is currently estimated to be $10 billion and projected to grow to $47 billion over the same period. With the development of this product LBC Bioscience is positioning itself to be a leader in the specialized CBD + e-cigarette vaping market. Initial responses from the market testing have exceeded expectations and pre-orders are already coming in for the product.
“The market for an application like this is immeasurable,” stated Lisa Nelson, President & CEO of CBD Life Science. “Combine the CBD phenonium with the current vaping trend and you have a no brainer. The feedback from our initial market testing was phenomenal resulting in pre-orders already coming in. This product is going to be a best seller…without a doubt,” continued Ms. Nelson.
About CBD Life Sciences Inc.
CBD Life Sciences Inc. is a publicly traded company having its common shares quoted on the OTC Markets under the symbol “CBDL”. The Company’s main focus is to identify, evaluate and acquire undervalued opportunities with the objective of increasing shareholder value. The acquisition of LBC Bioscience Inc. is the first in the CBD space and the company is actively searching for additional opportunities within this emerging sector.
About LBC Bioscience Inc.
LBC Bioscience Inc. is a wholly owned subsidiary of CBD Life Sciences Inc. LBC has developed and is retailing/wholesaling a full line of cannabidiol based organic products including: hemp drops, massage oils, pain relief creams, anxiety and sleep supplements, CDB edibles, anti-aging skin solutions and a full line of CBD infused supplements for your pets. LBC’s products can be viewed and purchased on the company’s website at www.lbcbioscience inc.com.
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See Optium Cyber Systems, Inc.’s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management’s current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Contact Information Investor Relations Ten Associates LLC 11529 N. 120th St. Scottsdale, Arizona 85259 USA Telephone: 480-326-8577 Contact: Thomas E. Nelson Email: [email protected]